Abnormalities of autonomic control of the cardiovascular system are seen in chronic heart failure (CHF) and confer a poor prognosis. Nitric oxide appears to be important in the regulation of baroreflex control in health and in disease states. The antioxidant vitamin C increases nitric oxide bioavailability in CHF. We evaluated the effects of vitamin C on baroreceptor sensitivity (BRS) by sequence analysis in 100 CHF patients and 44 control subjects. Groups of 55 CHF patients and 22 controls were randomly allocated to receive a single intravenous injection of vitamin C (2 g) or placebo. In addition, 45 CHF patients were randomly allocated to receive a 4-week course of oral vitamin C (4 g/day) or placebo. An age-related reference range for BRS was developed in 22 healthy controls matched for age and gender to the CHF group. BRS was significantly impaired in the CHF group compared with age-matched older controls and young controls (6.9 + − 3.1, 12.5 + − 4.9 and 21.7 + − 9.1 mmHg/ms respectively; P < 0.001 between groups). Intravenous vitamin C acutely improved BRS in CHF patients by 24 % (by 1.8 + − 4.1 mmHg/ms; P < 0.05), but not in controls. There was no improvement in BRS in CHF patients given chronic oral vitamin C. Thus acute intravenous, but not chronic oral, vitamin C improved BRS in CHF patients. There was no effect of intravenous vitamin C in healthy subjects, suggesting that the mechanism was either by free radical scavenging or due to central effects.
INTRODUCTION
Impaired baroreflex control of the heart and peripheral circulation is thought to play an important pathophysiological role in chronic heart failure (CHF) and confers a poor prognosis [1] [2] [3] . Baroreflex dysfunction is believed to be a key factor leading to increased sympathetic neural outflow and neurohumoral activation in CHF [4] . Some studies, however, have suggested that baroreflex dysfunction may be due to, rather than the cause of, increased sympathetic activation [5] . Evidence from animal studies suggests that the pathophysiology of the disturbance is complex, and includes reduced afferent baroreflex activity, increased cardiac sympathetic afferent activity, altered central (brainstem) gain and ganglionic abnormalities [6] .
A potentially important role of nitric oxide (NO) within the brainstem as a regulator of baroreceptor sensitivity (BRS) has been highlighted recently. In healthy subjects, systemic blockade of NO synthesis with N Gmonomethyl-l-arginine reduced BRS [7] . Furthermore, carotid and aortic NO bioavailability may alter BRS either via effects on arterial distensibility [8] or via direct effects of NO or superoxide anion on baroreceptor firing [9, 10] .
We [11] and others [12] have shown that vitamin C, given either acutely or chronically, can improve the vascular bioavailability of NO. Very high levels of ascorbic acid, typically > 1000 µM (as achieved transiently after an intravenous dose), may act predominantly by scavenging superoxide anions [13] , while chronic oral therapy, which results in lower levels (≈100 µM), may increase NO production and also replenish intracellular antioxidants [14] . We hypothesized that vitamin C might improve BRS by three mechanisms: first, by improving arterial distensibility (thus increasing baroreflex firing); secondly, by directly reducing the inhibitory effect of reactive oxygen species on baroreceptor nerve endings; and thirdly, by increasing NO availability within the cardiovascular regulatory centres of the brainstem. In order to investigate this hypothesis, we evaluated the impact of both acute intravenous and chronic oral vitamin C in a group of patients with CHF and in a healthy young (non-age matched) control group without cardiovascular risk factors. We assessed the effects of these interventions on baroreceptor sensitivity and on pulse wave velocity (PWV; a measure of arterial distensibility [15] ) in order to assess whether any improvement might be due, in part, to improved arterial distensibility. We chose to compare the response of CHF patients with that of young healthy controls (rather than age-matched controls) in order to assess the impact of vitamin C in a group with normal endothelial function and minimal oxidative stress.
METHODS

Subjects
We studied 100 patients with CHF referred to the University Hospital of Wales with a history of symptomatic heart failure and documented left ventricular systolic dysfunction (left ventricular ejection fraction 40%) of at least 3 months' duration. Exclusion criteria were rhythm other than sinus or more than 2 ectopics per min, diabetes mellitus, chronic renal impairment (creatinine 200 µmol/l), myocardial infarction in the last 6 months, current unstable angina, or vasovagal syncope. Patient symptom status and medical therapy had remained unchanged in the 4 weeks prior to the study. Therapy included angiotensin-converting enzyme (ACE) inhibitors in all patients, and β-blockers in 23% (see Table 3 ). In addition, 44 healthy volunteers with no cardiovascular risk factors were recruited as control subjects. None of the patients or controls was taking antioxidant vitamin supplements. All subjects gave written, informed consent, and the Local Research Ethics Committee approved the study.
Of the CHF patients, 55 were recruited to the acute study and 45 to the chronic study. Both were placebocontrolled double-blind studies conducted with parallel group design. In addition, 22 of the younger controls were selected to take part in an acute (placebo-controlled, double-blind, crossover) study. In order to define a normal age-related reference range for BRS, this was measured in 22 healthy subjects that were age-and gender-matched with the CHF patients. These subjects had only baseline measurements performed.
Study protocol
Subjects had fasted and abstained from caffeinecontaining drinks for at least 6 h. Diuretics were withheld on the morning of the study. The studies were performed in a quiet, temperature-controlled laboratory (22) (23) (24) • C) with the subject lying supine.
A three-lead ECG and beat-to-beat arterial blood pressure [Finapres (Ohmeda 2300) or Portapres (TNO Biomedical Instruments, Amsterdam, The Netherlands)] were recorded for 10 min, and data were acquired using a multi-channel data acquisition system (AcqKnowledge, Biopac) connected to a personal computer [16] . This method has been validated against the phenylephrine technique and shown to be more reproducible with fewer test failures, although the absolute values for BRS obtained are higher than with the phenylephrine technique [17] . The coefficient of variation in our laboratory for spontaneous BRS in CHF patients, measured 4 weeks apart, is 30% (in healthy controls, whose absolute BRS is higher, it is 14%).
These data were then examined for the presence of baroreflex sequences with R-R interval lags of 0 and 1. Sequences of three or more beats in which systolic blood pressure and R-R interval of the same (lag 0) or the subsequent (lag 1) beat changed in the same direction (either increasing or decreasing) were identified and linear regressions performed. Only regressions with r 2 values of > 0.85 were included. The slope of each individual sequence was computed, and the overall BRS was determined as the average of all slopes, calculated separately for lag 0 and lag 1. In order to assess whether changes in BRS were associated with changes in arterial distensibility, brachioradial PWV was assessed in the arm using an automated non-invasive commercially available peripheral pulse waveform recorder (QVLP84; SciMed, Bristol, U.K.) [18] . PWV was calculated as distance between cuffs divided by transit time.
Acute study A 19-gauge cannula was placed in the antecubital fossa of the non-dominant arm and flushed with normal saline. After 20 min of rest, 20 ml of saline was injected slowly. After 2 min, the ECG and blood pressure waveform were acquired for assessment of BRS. PWV was recorded for 10 min after the injection. Each subject was then randomly allocated to receive a second injection of either 20 ml of 0.9% saline or 2 g (20 ml) of vitamin C. BRS and PWV were determined again.
Chronic study
BRS and PWV were assessed in the manner described above after 20 min of supine rest. Subjects were then randomly allocated to receive 2 g of vitamin C orally twice a day or placebo. After 1 month, these measures were repeated. In both the acute and chronic studies, venous blood was obtained for measurement of ascorbic acid concentration, as described previously [19] .
Statistical analysis
Results are expressed as means + − S.D. Baseline characteristics in the three groups (control, CHF placebo and CHF vitamin C) were compared using one-way ANOVA. Significant differences between groups were then explored using the paired or unpaired Student's t test as appropriate. Responses to vitamin C and placebo in the CHF patients were compared using multivariate analysis of variance (MANOVA) to take into account the baseline values. A value of P < 0.05 was considered statistically significant. 
RESULTS
The clinical characteristics of the CHF patients and control subjects are shown in Table 1 . There were no significant differences in age, medication, NYHA (New York Heart Association) class, heart rate or blood pressure between the CHF patients that received vitamin C and those that received placebo in either the acute or the chronic study (Tables 2 and 3) .
BRS in CHF patients compared with controls
BRS was significantly impaired (P < 0.01 by ANOVA) in CHF patients (6.9 + − 3.1 mmHg/ms) compared with that in age-matched controls (12.5 + − 4.9 mmHg/ms), who in turn had a lower BRS than the young healthy control group (21.7 + − 9.1 mmHg/ms) ( Figure 1 ). This was true for both lag 0 and lag 1. As all groups had a heart rate of less than 75 beats/min, lag 0 was used as a better indicator 
Effect of acute vitamin C on BRS in CHF patients
Of the 55 CHF patients in this part of the study, five patients had frequent ectopics on the second Intravenous vitamin C caused a significant rise in the plasma ascorbic acid concentration (from 60.2 µmol/l to 786 µmol/l at 30 min post-injection; P < 0.001) and an increase in BRS of 1.8 + − 4.1 ms/mmHg (95% confidence interval 0.1-3.5 ms/mmHg), whereas there was no change with placebo ( − 0.3 + − 2.7 ms/mmHg; P < 0.05 by MANOVA for the difference between the two groups) ( Table 4 and Figure 2 ). There were no significant changes in heart rate or blood pressure (Table 4) . Brachio-radial PWV did not change significantly (Table 4) .
Effect of acute vitamin C on BRS in controls
In the healthy young controls, there were no significant changes in BRS following vitamin C, despite increases in plasma ascorbic acid concentration similar to those in the CHF patients (Table 5) . Similarly, PWV did not change.
Effect of chronic vitamin C on BRS in CHF patients
Of the 45 CHF patients in this part of the study, one subject in the vitamin C group and six in the placebo group were excluded due to frequent ectopics on the second visit. Full data were therefore available for 38 patients (15 receiving placebo and 23 receiving vitamin C). Baseline BRS did not differ significantly between the vitamin C and placebo groups (6.9 + − 2.8 and 7.5 + − 4.0 ms/ mmHg respectively. There was no significant change in BRS following vitamin C, despite a significant rise in plasma ascorbic acid to 127.3 + − 59.5 µmol/l (P < 0.001). PWV did not change with chronic oral vitamin C therapy (Table 6 ).
DISCUSSION
The integrity of the baroreflex pathway is crucial in cardiovascular homoeostasis. Dysfunction of this system is well described in heart failure and carries important prognostic information [1] [2] [3] . This manifests as impaired baroreflex control of heart rate in response to spontaneous or induced changes in blood pressure (impaired BRS) and augmented sympathetic outflow. The key finding of our present study was that acute intravenous vitamin C significantly augmented BRS in CHF patients, but did not affect BRS in healthy controls. Chronic oral vitamin C did not augment BRS in the CHF patients.
Effects of vitamin C on BRS
Vitamin C has antioxidant effects when given intravenously, as plasma levels are then sufficient to directly scavenge superoxide and hydroxyl radicals in plasma [13] . Plasma levels achieved by chronic oral therapy are probably insufficient to result in direct extracellular free radical scavenging [20] . Nevertheless, as discussed above, oral vitamin C therapy reduces oxidative stress and increases NO bioavailability [11] . Vitamin C also has other effects, not directly related to its antioxidant effects, that may be important [21] . The effects of vitamin C on BRS may occur at several points in the baroreflex arc. First, carotid and aortic baroreceptors respond to arterial pulsatile stretch; therefore reduced arterial distensibility might be expected to reduce baroreceptor firing. Carotid arterial distensibility has been shown to be reduced in CHF [22] , and this may be due in part to impaired endothelial function [15] . We and others have shown that vitamin C can improve endothelial function [11, 12] ; however, in the present study there was no improvement in distensibility of large arteries in the arm (measured by PWV), suggesting that this was not the mechanism responsible for the improvement in BRS. In an animal model, free radicals have been shown to directly inhibit the firing of arterial baroreceptors [9] . Free radicals have also been shown to increase the firing of cardiac sympathetic afferent fibres [10] . Direct free radical scavenging in plasma might therefore explain at least some of the effects of the acute intravenous vitamin C via these mechanisms. The lack of an effect on BRS of chronic oral vitamin C supplementation might be due to the absence of free radical scavenging at lower concentrations [13] .
There are at least two other potential mechanisms whereby vitamin C might improve BRS: first, by altering the level of NO in the brainstem [23] , and secondly, by a direct influence on sinus node automaticity via effects on I f channels [24] . Our study does not allow us to explore these potential mechanisms.
Chowdhary et al. [7] have shown that systemic infusion of N G -monomethyl-l-arginine impairs BRS in healthy control subjects, implying that basal NO activity has an important role in BRS. Our observations suggest that increasing NO bioavailability above basal levels and/or reducing oxidative stress increases BRS in CHF patients, but not in healthy subjects.
Study limitations
This was a study of patients with mild to moderate heart failure who were on optimal medical treatment, which was continued throughout the study. This medication had the potential to improve BRS; specifically, ACE inhibitors [25, 26] , β-blockers [27] and digoxin [28] can improve BRS. However, apart from vitamin C, all other medication remained constant. MANOVA took account of baseline differences in BRS. We did not measure oxidative stress in the present study, but have previously shown a decrease in lipid-derived free radicals with both acute and chronic vitamin C in a similar study population [11] . Brachio-radial PWV was not significantly different between the CHF patients and controls. This may be an effect of medication, as other groups have shown similar findings [29] . We used brachio-radial PWV as a surrogate marker of carotid distensibility; therefore conclusions regarding this as a potential mechanism need to be interpreted with caution.
The methodology for assessment of BRS in the present study was spontaneous sequence analysis. It is possible to perform cross-spectral analysis on blood pressure and heart rate data to obtain the α-index in both the lowand high-frequency bands. This is most effective when combined with controlled breathing. Our study did not use controlled breathing, and therefore detecting the high-frequency peak becomes prone to error. One study that compared the values of BRS measured using spontaneous sequence analysis and cross-spectral analysis with controlled breathing showed that the sequence analysis and controlled breathing techniques provided similar results (although controlled breathing resulted in fewer test failures) [17] . Had we used controlled breathing, it may have resulted in fewer test failures (12 out of 262 in the present study), but is unlikely to have influenced the overall result.
Clinical implications
Impaired BRS is associated with a poor outcome in CHF patients [1] . This association may be explained, in part, by an increased risk of arrhythmias and sudden death in patients with baroreflex dysfunction [3] . Furthermore, it appears likely that reduced baroreceptor activity leads to increased sympathetic outflow, contributing to neurohumoral activation in heart failure, which is also known to be associated with reduced life expectancy [4] . Measures aimed at increasing baroreflex activity may therefore be beneficial in the setting of heart failure.
We have demonstrated that acute treatment with intravenous vitamin C improves BRS by 24% in patients with CHF; this effect was not seen in healthy young control subjects. These observations suggest an important contribution of reduced NO bioavailability and/or increased oxidative stress to baroreflex dysfunction in CHF. The lack of an effect of chronic oral vitamin C on BRS suggests that such therapy is therefore unlikely to be of clinical benefit. Nevertheless, other therapies targeted towards this mechanism might be investigated regarding potential benefit.
Conclusions
Acute intravenous, but not chronic oral, vitamin C improved BRS in CHF patients. There was no effect of intravenous vitamin C in healthy subjects, suggesting that the mechanism is more likely to be mediated via free radical scavenging or to be due to central effects relating to increased bioavailability of NO, rather than to improvements in arterial distensibility.
